MAD2L1bindingprotein抗体;MAD2L1bindingprotein Antibody—艾普蒂 新品

+ +

•  

   

     Western blot analysis of MAD2L1BP expression in A431 cell lysate.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human kidney, using MAD2L1BP Antibody.    

  
  

The MAD2L1-binding protein antibody is a crucial tool for studying the spindle assembly checkpoint (SAC), a surveillance mechanism ensuring accurate chromosome segregation during mitosis. MAD2L1 (Mitotic Arrest Deficient 2-Like 1) is a core SAC component that binds to kinetochores unattached to spindle microtubules, forming the Mitotic Checkpoint Complex (MCC) with BUBR1. CDC20. and other proteins. This complex inhibits the anaphase-promoting complex/cyclosome (APC/C) until all chromosomes achieve proper attachment, preventing premature anaphase onset.

Antibodies targeting MAD2L1 or its binding partners (e.g., MAD1. CDC20) are widely used to investigate SAC dynamics, chromosome missegregation, and genomic instability. They enable detection of protein-protein interactions via co-immunoprecipitation, localization studies using immunofluorescence, and quantification via Western blotting. Dysregulation of MAD2L1 or its interactors is linked to aneuploidy and tumorigenesis, making these antibodies valuable in cancer research. For example, reduced MAD2L1 expression correlates with aggressive cancers, while overexpression may drive chemoresistance.

These reagents also aid in studying SAC-targeting therapies and mechanisms underlying developmental disorders linked to chromosomal instability. Specificity and validation (e.g., knockout cell controls) are critical, as off-target binding can obscure SAC-related phenotypes. Overall, MAD2L1-binding protein antibodies are indispensable for dissecting cell cycle regulation and its pathological disruptions.